Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARITEP: 5-HT2A Imaging in Tourette Disorder
NCT05942716Phase 2Recruiting
- Sponsor
- Hospices Civils de Lyon
- Start
- Sep 2024
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aripiprazole in Tourette syndrome (TS), sponsored by Hospices Civils de Lyon. Primary endpoint: Correlation coefficients between receptor-specific imaging data (PET) and scores of impulsivity measured by the Barratt scale (BIS11). Started Sep 2024; status: recruiting.
02
Drugs
aripiprazole
03
Conditions
Tourette syndrome (TS)
Beyond the preview
Go deeper on NCT05942716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05942716.